Trastuzumab cost effective in HER2-positive breast cancer

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.527, 2007-01, pp. : 4-4

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Trastuzumab cost effective in HER2-positive breast cancer

By  

Inpharma, Vol. 1, Iss. 1586, 2007-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Preoperative trastuzumab, docetaxel and carboplatin therapy is effective for HER2-positive breast cancer

By  

Inpharma, Vol. 1, Iss. 1592, 2007-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Trastuzumab: In HER2 and Hormone Receptor Co-Positive Metastatic Breast Cancer

By Orman Jennifer S.   Perry Caroline M.  

Drugs, Vol. 67, Iss. 18, 2007-01 ,pp. : 2781-2789

Adis International

Access to resources Recommend Favorite

HER-2-positive metastatic breast cancer: trastuzumab and beyond

By Metro Giulio   Mottolese Marcella   Fabi Alessandra  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 15, 2008-10 ,pp. : 2583-2601

Informa Healthcare

Access to resources Recommend Favorite

‘Simply stunning’ – trastuzumab in HER2-positive breast cancer

By Doggrell Sheila A  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 5, 2006-04 ,pp. : 631-634

Informa Healthcare

Access to resources Recommend Favorite